Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil

BACKGROUND: Palivizumab prophylaxis for the human respiratory syncytial virus (HRSV) has been reported to reduce the risk of hospital admissions related to HRSV in children with congenital heart disease (CHD). These children are at high risk of developing severe lower respiratory tract infection (LR...

Descripción completa

Detalles Bibliográficos
Autores principales: de Souza, Roseane Porfírio, Ribeiro, Andre Luis Ribeiro, de Menezes, Sílvio Augusto Fernandes, Machado, Luiz Fernando Almeida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714430/
https://www.ncbi.nlm.nih.gov/pubmed/31462289
http://dx.doi.org/10.1186/s12887-019-1681-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714430/
https://www.ncbi.nlm.nih.gov/pubmed/31462289
http://dx.doi.org/10.1186/s12887-019-1681-6

Ejemplares similares